Category Covid-19

PIER MARIA FORNASARI
2021-12-05

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia: results of Italian TSUNAMI randomized clinical trial

1. Amongst patients with severe COVID-19 pneumonia, there was no difference in 30-day all-cause mortality, ventilation or cure in patients receiving convalescent plasma (CP) plus standard therapy versus standard therapy alone. 2. CP treatment was associated with more adverse events, including 5 instances of respiratory failure requiring treatment interruption. Patients who have recovered from SARS-CoV-2

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-04

A detailed study by Max Planck Institute shows the maximum risks of being infected by SARS-CoV-2 for different scenarios with and without masks

Three metres are not enough to ensure protection. Even at that distance, it takes less than five minutes for an unvaccinated person standing in the breath of a person with Covid-19 to become infected with almost 100 percent certainty. That’s the bad news. The good news is that if both are wearing well-fitting medical or,

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-03

Scientists of Arizona State University discover potential mechanism behind rare blood clots linked to adenovirus COVID-19 vaccines (VITT)

A cloud of platelet factor 4 proteins interacts with the electrostatic surface of the Oxford vaccine, as seen through the computational microscope.  An international team of scientists believe they may have found a molecular mechanism behind the extremely rare blood clots linked to adenovirus COVID-19 vaccines. “The mechanism which results in this condition, termed vaccine-induced

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-03

Safety and immunogenicity of booster COVID-19 vaccine following two previous doses of AstraZeneca or Pfizer-BioNTech in the UK

Six different COVID-19 boosters are safe and provoke strong immune responses in people who have previously received a two-dose course of ChAdOx1-nCov19 (Oxford–AstraZeneca [ChAd]) or BNT162b2 (Pfizer-BioNTech [BNT]), according to the first randomised trial of boosters given after two doses of either vaccine, published in The Lancet. ChAd has now been deployed in more than 180

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-03

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. A comment on The Lancet by researchers of Centre for the AIDS Programme of Research in South Africa

A new comment on Omicron SARS-CoV-2 variant has been published on The Lancet by South African researchers of Centre for the AIDS Programme of Research in Durban South Africa. The Authors highlight that the first sequenced omicron case was reported from Botswana on Nov 11, 2021, and a few days lateranother sequenced case was reported

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-02

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa 2021-12-01: new paper published in medRxiv

Objective of the paper is to examine whether SARS-CoV-2 reinfection risk has changed through time in South Africa, in the context of the emergence of the Beta, Delta, and Omicron variants A retrospective analysis of routine epidemiological surveillance data Setting Line list data on SARS-CoV-2 with specimen receipt dates between 04 March 2020 and 27

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-27

No increased risk of Myocardial Infarction, Stroke and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older: French study published in JAMA

A French population-based study provides further evidence that the BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine does not increase the short-term risk for serious cardiovascular adverse events in older people. The study showed no increased risk of myocardial infarction (MI), stroke, or pulmonary embolism (PE) following vaccination in adults aged 75 years or older in the 14 days following vaccination. “These

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-27

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529) Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant. The recently described Omicron

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-11-27

Scientific analysis of COVID death data incorrectly manipulated to demonstrate vaccines are ineffective or worse: that’s not the reality

Social media posts commenting on data from the UK, Israel and South Africa, among others, claim deaths from COVID (or all deaths) are now higher in vaccinated than unvaccinated citizens. Others make the more moderate claim vaccines do nothing to prevent death from COVID. These reports appear intimidating, because they usually utilise real data or statistics. Many of the raw numbers presented are

Read More

No Comments InCovid-19